Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today ...
After hours: 7:59:51 p.m. EST Loading Chart for SLXN ...
After hours: February 21 at 7:59:51 PM EST ...
P/E ratio (year end quote, basic EPS) 253.37 259.61 - - P/E ratio (year end quote, diluted EPS) 253.37 259.61 - - Silexion Therapeutics Dividend Calendar Silexion Therapeutics Calendar Indices ...
After hours: February 18 at 6:56:12 p.m. EST ...
After hours: 7:49:30 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results